Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Dec;28(12):851.e1-851.e8.
doi: 10.1016/j.jtct.2022.09.007. Epub 2022 Sep 20.

Impact of Cytomegalovirus Replication in Patients with Aggressive B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy

Ester Márquez-Algaba  1 , Gloria Iacoboni  2 , Berta Pernas  3 , Juliana Esperalba  4 , Ibai Los Arcos  5 , Victor Navarro  6 , Arnau Monforte  1 , Francisco Beas  7 , Adaia Albasanz-Puig  5 , Cecilia Carpio  2 , Pere Barba  8 , Isabel Ruiz-Camps  1
Affiliations
Free article
Observational Study

Impact of Cytomegalovirus Replication in Patients with Aggressive B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy

Ester Márquez-Algaba et al. Transplant Cell Ther. 2022 Dec.
Free article

Abstract

Data are scarce on cytomegalovirus (CMV) replication in patients receiving CD19-directed chimeric antigen receptor (CAR) T cell treatment. Here we describe the incidence, severity, and management of CMV infection in patients with aggressive B cell lymphoma treated with CAR T cell therapy. In this retrospective observational study, we analyzed CMV viral load and its clinical impact in patients with aggressive B cell lymphoma receiving CAR T cell therapy between July 2018 and December 2021 at a single center. Patients with a negative baseline CMV IgG or a previous allogeneic stem cell transplantation were excluded. CMV replication was determined in whole blood. Overall, 105 patients met the study's inclusion criteria. Ten patients presented with CMV replication before CAR T cell infusion and were analyzed separately. Forty-two of the remaining 95 patients (44%) had at least 1 positive CMV determination, with a viral load ≥1000 IU/mL in 21 patients (22%). Four patients in the main cohort (N = 95) and 4 patients in the preinfusion replication group (N = 10) achieved a viral load >10,000 IU/mL. Only 7 patients received preemptive antiviral treatment. No CMV end-organ disease was reported. The sole independent risk factor associated with CMV viremia ≥1000 IU/mL was dexamethasone treatment (odds ratio, 8.4; 95% confidence interval, 2.4 to 36.6; P = .002). Based on our findings, we designed an algorithm for CMV management in this setting. CMV replication is relatively frequent in patients with aggressive B cell lymphoma receiving CAR T cell therapy. It is usually self-limited and not associated with end-organ disease. Patients receiving dexamethasone or harboring CMV replication before infusion might benefit from active surveillance and preemptive treatment strategies.

Keywords: Aggressive B cell lymphoma; CAR T cell therapy; Cytomegalovirus replication; Cytomegalovirus surveillance.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest G.I. reports consultancy and/or honoraria from Novartis, Roche, Kite/Gilead, Bristol-Myers Squibb, AbbVie, Janssen, Sandoz, Miltenyi Biotec, and AstraZeneca. P.B. reports consultancy for Allogene, Amgen, BMS, Gilead, Miltenyi Biomedicine, Incyte, Novartis, and Pfizer; data safety monitoring board (clinical trials) for Miltenyi Biotec; speakers bureau for Amgen, BMS, Gilead, Novartis, and Pfizer; and travel and accommodation expenses from Gilead, Novartis, and Pfizer.

Publication types

MeSH terms